JP2007511487A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007511487A5 JP2007511487A5 JP2006538825A JP2006538825A JP2007511487A5 JP 2007511487 A5 JP2007511487 A5 JP 2007511487A5 JP 2006538825 A JP2006538825 A JP 2006538825A JP 2006538825 A JP2006538825 A JP 2006538825A JP 2007511487 A5 JP2007511487 A5 JP 2007511487A5
- Authority
- JP
- Japan
- Prior art keywords
- injury
- heart failure
- drug
- dpp
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000006378 damage Effects 0.000 claims 13
- 206010019280 Heart failures Diseases 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 10
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 9
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 208000017169 kidney disease Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- -1 3-hydroxy-1-adamantyl Chemical group 0.000 claims 5
- 208000021479 Cardiovascular injury Diseases 0.000 claims 5
- 206010061481 Renal injury Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000037806 kidney injury Diseases 0.000 claims 5
- 206010020772 Hypertension Diseases 0.000 claims 4
- ZHUTVLURGLOKMO-UHFFFAOYSA-N 1-acetylpyrrolidine-2-carbonitrile Chemical compound CC(=O)N1CCCC1C#N ZHUTVLURGLOKMO-UHFFFAOYSA-N 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 230000008719 thickening Effects 0.000 claims 3
- 210000005166 vasculature Anatomy 0.000 claims 3
- UIKDPMGTFQHKLC-UHFFFAOYSA-N 3-(aminomethyl)-2-(2-methylpropyl)-1-oxo-4-phenylisoquinoline-6-carboxamide Chemical compound C12=CC(C(N)=O)=CC=C2C(=O)N(CC(C)C)C(CN)=C1C1=CC=CC=C1 UIKDPMGTFQHKLC-UHFFFAOYSA-N 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 2
- 206010037368 Pulmonary congestion Diseases 0.000 claims 2
- 208000024248 Vascular System injury Diseases 0.000 claims 2
- 208000012339 Vascular injury Diseases 0.000 claims 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 2
- 230000001969 hypertrophic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000009925 nephrosclerosis Diseases 0.000 claims 2
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims 2
- 229960004937 saxagliptin Drugs 0.000 claims 2
- 108010033693 saxagliptin Proteins 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 208000000924 Right ventricular hypertrophy Diseases 0.000 claims 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 230000009861 stroke prevention Effects 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52056303P | 2003-11-17 | 2003-11-17 | |
| US52056203P | 2003-11-17 | 2003-11-17 | |
| US54719204P | 2004-02-24 | 2004-02-24 | |
| US54719104P | 2004-02-24 | 2004-02-24 | |
| PCT/EP2004/012990 WO2005049022A2 (en) | 2003-11-17 | 2004-11-16 | Use of dipeptidyl peptidase iv inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012123284A Division JP2012211146A (ja) | 2003-11-17 | 2012-05-30 | ジペプチジルペプチダーゼｉｖ阻害剤の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007511487A JP2007511487A (ja) | 2007-05-10 |
| JP2007511487A5 true JP2007511487A5 (enExample) | 2008-02-07 |
Family
ID=34623985
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538825A Withdrawn JP2007511487A (ja) | 2003-11-17 | 2004-11-16 | ジペプチジルペプチダーゼｉｖ阻害剤の使用 |
| JP2012123284A Withdrawn JP2012211146A (ja) | 2003-11-17 | 2012-05-30 | ジペプチジルペプチダーゼｉｖ阻害剤の使用 |
| JP2014075331A Expired - Fee Related JP6312502B2 (ja) | 2003-11-17 | 2014-04-01 | ジペプチジルペプチダーゼｉｖ阻害剤の使用 |
| JP2016123464A Withdrawn JP2016222677A (ja) | 2003-11-17 | 2016-06-22 | ジペプチジルペプチダーゼｉｖ阻害剤の使用 |
| JP2017188912A Withdrawn JP2018039816A (ja) | 2003-11-17 | 2017-09-28 | ジペプチジルペプチダーゼｉｖ阻害剤の使用 |
| JP2020119890A Pending JP2020183412A (ja) | 2003-11-17 | 2020-07-13 | ジペプチジルペプチダーゼｉｖ阻害剤の使用 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012123284A Withdrawn JP2012211146A (ja) | 2003-11-17 | 2012-05-30 | ジペプチジルペプチダーゼｉｖ阻害剤の使用 |
| JP2014075331A Expired - Fee Related JP6312502B2 (ja) | 2003-11-17 | 2014-04-01 | ジペプチジルペプチダーゼｉｖ阻害剤の使用 |
| JP2016123464A Withdrawn JP2016222677A (ja) | 2003-11-17 | 2016-06-22 | ジペプチジルペプチダーゼｉｖ阻害剤の使用 |
| JP2017188912A Withdrawn JP2018039816A (ja) | 2003-11-17 | 2017-09-28 | ジペプチジルペプチダーゼｉｖ阻害剤の使用 |
| JP2020119890A Pending JP2020183412A (ja) | 2003-11-17 | 2020-07-13 | ジペプチジルペプチダーゼｉｖ阻害剤の使用 |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP1686994A2 (enExample) |
| JP (6) | JP2007511487A (enExample) |
| KR (10) | KR20170104639A (enExample) |
| CN (1) | CN1905876B (enExample) |
| AU (2) | AU2004290897B2 (enExample) |
| BR (1) | BRPI0416628A (enExample) |
| CA (1) | CA2545641A1 (enExample) |
| MX (1) | MXPA06005518A (enExample) |
| WO (1) | WO2005049022A2 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| AU2005289756B2 (en) * | 2004-09-22 | 2011-10-13 | Tripath Imaging, Inc. | Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| BRPI0608469A2 (pt) | 2005-04-22 | 2010-01-05 | Alantos Pharmaceuticals Holding Inc | inibidores de dipeptidil peptidase-iv |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| LT2007416T (lt) * | 2006-04-19 | 2018-02-12 | Ludwig-Maximilians-Universität München | Paratiroidinis hormonas (pth), skirtas naudoti išemijos gydymui |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| SG174054A1 (en) | 2006-05-04 | 2011-09-29 | Boehringer Ingelheim Int | Polymorphs |
| AU2008210988B2 (en) * | 2007-02-01 | 2012-09-06 | Allocure, Inc. | Potentiation of stem cell homing and treatment of organ dysfunction or organ failure |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| WO2009024542A2 (en) * | 2007-08-17 | 2009-02-26 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
| EP2096171A1 (en) * | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| KR20110067096A (ko) | 2008-09-10 | 2011-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 및 관련 상태를 치료하기 위한 병용 요법 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| EA022310B1 (ru) | 2008-12-23 | 2015-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Солевые формы органического соединения |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| SG173619A1 (en) | 2009-02-13 | 2011-09-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
| KR20110135411A (ko) * | 2009-03-27 | 2011-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | Ｄｐｐ-ｉｖ 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법 |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| BR112012012641A2 (pt) | 2009-11-27 | 2020-08-11 | Boehringer Ingelheim International Gmbh | TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA |
| JP2013523819A (ja) | 2010-04-06 | 2013-06-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
| CA2803504C (en) | 2010-06-24 | 2022-08-30 | Boehringer Ingelheim International Gmbh | A combination for diabetes therapy comprising linagliptin and a long-acting insulin |
| SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EP3517539B1 (en) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| HUE041709T2 (hu) | 2013-04-05 | 2019-05-28 | Boehringer Ingelheim Int | Az empagliflozin terápiás alkalmazásai |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| HK1213818A1 (zh) | 2013-04-05 | 2016-07-15 | 勃林格殷格翰国际有限公司 | 依帕列净的治疗用途 |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PT2986304T (pt) | 2013-04-18 | 2022-02-25 | Boehringer Ingelheim Int | Composição farmacêutica, métodos para o tratamento e suas utilizações |
| BR112015032410B8 (pt) | 2013-06-26 | 2021-10-26 | Dong A St Co Ltd | Uso de uma composição farmacêutica compreendendo inibidores de dpp-iv no preparo de um medicamento para prevenção ou tratamento de doenças renais |
| JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｐｐ−４阻害薬の医学的使用 |
| WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| AU2017357589B2 (en) | 2016-11-10 | 2023-05-11 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| KR20200036808A (ko) | 2017-04-03 | 2020-04-07 | 코히러스 바이오사이언시스, 인크. | 진행성 핵상 마비 치료를 위한 PPARγ 작용제 |
| KR20190019542A (ko) | 2017-08-18 | 2019-02-27 | 현대자동차주식회사 | 차량용 쿨러 |
| KR102142559B1 (ko) | 2018-07-31 | 2020-08-07 | 가톨릭대학교 산학협력단 | Dpp4 억제제를 유효성분으로 포함하는 심근섬유증의 예방 또는 치료용 조성물 |
| EP4335438A1 (en) | 2019-09-17 | 2024-03-13 | Novartis AG | Combination therapy with vildagliptin and metformin |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9206628A (es) | 1991-11-22 | 1993-05-01 | Boehringer Ingelheim Pharma | Ester de prolinaboronato y metodo para su preparacion. |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5935924A (en) | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
| US5543396A (en) | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
| IL126175A (en) | 1996-04-04 | 2003-05-29 | Banyu Pharma Co Ltd | Pharmaceutical compositions containing endothelin antagonists and novel endothelin antagonists |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US5998458A (en) | 1997-06-25 | 1999-12-07 | University Technology Corporation | Method of treating heart failure |
| EP1043328B1 (en) | 1997-11-18 | 2008-03-19 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Novel physiologically active substance sulphostin, process for producing the same, and use thereof |
| AU766219B2 (en) | 1998-02-02 | 2003-10-09 | 1149336 Ontario Inc. | Method of regulating glucose metabolism, and reagents related thereto |
| AU3034299A (en) | 1998-03-09 | 1999-09-27 | Fondatech Benelux N.V. | Serine peptidase modulators |
| DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| DE19835500C1 (de) * | 1998-08-06 | 2000-03-16 | Duerkopp Adler Ag | Schneidvorrichtung zur Erzeugung einer Schlitzöffnung für ein Knopfloch |
| WO2000010549A1 (en) * | 1998-08-21 | 2000-03-02 | Point Therapeutics, Inc. | Regulation of substrate activity |
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| WO2001034594A1 (en) | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| KR20020063260A (ko) * | 1999-12-23 | 2002-08-01 | 노파르티스 아게 | 당 대사 장애를 치료하기 위한 혈당강하제의 용도 |
| JP2003520226A (ja) | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物 |
| JP2003520849A (ja) | 2000-01-24 | 2003-07-08 | ノボ ノルディスク アクティーゼルスカブ | 酵素ｄｐｐ−ｉｖの阻害剤であるｎ−置換２−シアノピロールおよび−ピロリン |
| US7087608B2 (en) | 2000-03-03 | 2006-08-08 | Robert Charles Atkins | Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| AU2001254763A1 (en) | 2000-03-31 | 2001-10-08 | Prosidion Limited | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| US6482844B1 (en) | 2000-04-07 | 2002-11-19 | Neurogen Corporation | 1-benzylimidazole derivatives |
| GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
| WO2002002560A2 (en) | 2000-07-04 | 2002-01-10 | Novo Nordisk A/S | Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
| DK1308439T3 (da) | 2000-08-10 | 2009-01-12 | Mitsubishi Tanabe Pharma Corp | Prolinderivater og anvendelse af disse som lægemidler |
| NZ524974A (en) | 2000-10-06 | 2005-10-28 | Tanabe Seiyaku Co | Aliphatic nitrogen-containing 5-membered ring compound |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| WO2002053548A1 (fr) | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Derives de la benzothiazepine |
| WO2002051836A1 (en) | 2000-12-27 | 2002-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
| DE10100053A1 (de) * | 2001-01-02 | 2002-08-22 | Keyneurotek Ag I G | Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen |
| MXPA03006918A (es) | 2001-02-02 | 2004-05-24 | Takeda Chemical Industries Ltd | Compuestos heterociclicos fusionados. |
| WO2002066627A1 (en) | 2001-02-16 | 2002-08-29 | Bayer Aktiengesellschaft | Regulation of human dipeptidyl peptidase 8 |
| HU230384B1 (hu) | 2001-02-24 | 2016-03-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként |
| WO2002067918A1 (en) | 2001-02-27 | 2002-09-06 | Banyu Pharmaceutical Co., Ltd. | Novel diallylmethylamine derivative |
| DE60226723D1 (de) | 2001-03-27 | 2008-07-03 | Merck & Co Inc | Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes |
| FR2822826B1 (fr) | 2001-03-28 | 2003-05-09 | Servier Lab | Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB0109146D0 (en) | 2001-04-11 | 2001-05-30 | Ferring Bv | Treatment of type 2 diabetes |
| US6573287B2 (en) * | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20030060494A1 (en) | 2001-05-18 | 2003-03-27 | Nobuyuki Yasuda | Pharmaceutical use of N-carbamoylazole derivatives |
| SE523510C2 (sv) | 2001-05-18 | 2004-04-27 | Jan G Faeger | Förfarande för att fastställa en varelses position och/eller orientering i förhållande till en omgivning |
| WO2003000180A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| US7253172B2 (en) | 2001-06-20 | 2007-08-07 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| CN1990468A (zh) | 2001-06-27 | 2007-07-04 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
| US20030005443A1 (en) | 2001-06-27 | 2003-01-02 | Karin Axelsson | EPG having PIP window history and sample view functionality |
| CA2419888A1 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| ATE370943T1 (de) * | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
| JP4300108B2 (ja) * | 2001-06-27 | 2009-07-22 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのピロリジン類 |
| WO2003003250A1 (en) | 2001-06-28 | 2003-01-09 | Hywire Ltd. | Range content-addressable memory |
| JP2003012575A (ja) | 2001-06-29 | 2003-01-15 | Idemitsu Petrochem Co Ltd | アダマンタノール及びアダマンタノンの製造法 |
| EP1404675B1 (en) | 2001-07-03 | 2008-03-12 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| WO2003024942A1 (en) | 2001-09-14 | 2003-03-27 | Mitsubishi Pharma Corporation | Thiazolidine derivative and medicinal use thereof |
| EP1463727A2 (en) | 2001-09-19 | 2004-10-06 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
| GB0125445D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
| GB0125446D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Novel anti-diabetic agents |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| JP2005507261A (ja) * | 2001-10-31 | 2005-03-17 | ノバルティス アクチエンゲゼルシャフト | Ｔｃｆ１遺伝子における多型に基づく糖尿病および関連状態の治療方法 |
| JP2005513165A (ja) | 2002-01-11 | 2005-05-12 | ノボ ノルディスク アクティーゼルスカブ | 糖尿病、高血圧、慢性心不全および体液貯留状態の治療のための方法および組成物 |
| BR0307665A (pt) | 2002-02-13 | 2005-01-04 | Hoffmann La Roche | Compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades associadas com dpp iv e utilização dos compostos |
| HUP0200849A2 (hu) * | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
| TW200810743A (en) * | 2002-03-22 | 2008-03-01 | Novartis Ag | Combination of organic compounds |
| WO2003084940A1 (en) | 2002-04-08 | 2003-10-16 | Alangudi Sankaranarayanan | Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors |
| EP1537880A4 (en) | 2002-09-11 | 2009-07-01 | Takeda Pharmaceutical | Sustained release preparation |
| MXPA05004063A (es) | 2002-10-18 | 2005-06-08 | Merck & Co Inc | Inhibidores de la beta-amino heterociclico dipeptidil peptidasa para el tratamiento o prevencion de diabetes. |
| AU2003282983A1 (en) | 2002-10-23 | 2004-05-13 | Bristol-Myers Squibb Company | Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods |
| DE10256264A1 (de) | 2002-12-03 | 2004-06-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| WO2004071454A2 (en) | 2003-02-13 | 2004-08-26 | Guilford Pharmaceuticals Inc. | Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv |
| AU2003207881A1 (en) | 2003-02-28 | 2004-09-17 | Aic | Dipeptidyl peptidase inhibitors |
-
2004
- 2004-11-16 KR KR1020177024680A patent/KR20170104639A/ko not_active Withdrawn
- 2004-11-16 KR KR1020127028863A patent/KR20120126133A/ko not_active Withdrawn
- 2004-11-16 KR KR1020127000489A patent/KR20120008093A/ko not_active Withdrawn
- 2004-11-16 CN CN2004800405089A patent/CN1905876B/zh not_active Expired - Fee Related
- 2004-11-16 BR BRPI0416628-0A patent/BRPI0416628A/pt not_active Application Discontinuation
- 2004-11-16 KR KR1020067009502A patent/KR20060109911A/ko not_active Withdrawn
- 2004-11-16 KR KR1020147014776A patent/KR20140089408A/ko not_active Withdrawn
- 2004-11-16 MX MXPA06005518A patent/MXPA06005518A/es active IP Right Grant
- 2004-11-16 KR KR1020187012266A patent/KR20180050427A/ko not_active Ceased
- 2004-11-16 EP EP04797932A patent/EP1686994A2/en not_active Withdrawn
- 2004-11-16 KR KR20157002440A patent/KR20150028829A/ko not_active Withdrawn
- 2004-11-16 JP JP2006538825A patent/JP2007511487A/ja not_active Withdrawn
- 2004-11-16 EP EP14190100.9A patent/EP2839832A3/en not_active Withdrawn
- 2004-11-16 WO PCT/EP2004/012990 patent/WO2005049022A2/en not_active Ceased
- 2004-11-16 CA CA002545641A patent/CA2545641A1/en not_active Abandoned
- 2004-11-16 KR KR1020157032295A patent/KR20150132601A/ko not_active Ceased
- 2004-11-16 AU AU2004290897A patent/AU2004290897B2/en not_active Ceased
- 2004-11-16 KR KR1020167036999A patent/KR20170005163A/ko not_active Withdrawn
- 2004-11-16 KR KR1020137021480A patent/KR20130105741A/ko not_active Withdrawn
-
2009
- 2009-05-26 AU AU2009202080A patent/AU2009202080A1/en not_active Abandoned
-
2012
- 2012-05-30 JP JP2012123284A patent/JP2012211146A/ja not_active Withdrawn
-
2014
- 2014-04-01 JP JP2014075331A patent/JP6312502B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-22 JP JP2016123464A patent/JP2016222677A/ja not_active Withdrawn
-
2017
- 2017-09-28 JP JP2017188912A patent/JP2018039816A/ja not_active Withdrawn
-
2020
- 2020-07-13 JP JP2020119890A patent/JP2020183412A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007511487A5 (enExample) | ||
| JP2008515905A5 (enExample) | ||
| JP2021095409A (ja) | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 | |
| US20060111428A1 (en) | Combination of an dpp-iv inhibitor and a ppar-alpha compound | |
| US20070149451A1 (en) | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent | |
| US20040023840A1 (en) | Combination of organic compounds | |
| US20110301172A1 (en) | Combination of dpp-iv inhibitor, ppar antidiabetic and metmorformin | |
| JP2007511486A5 (enExample) | ||
| JP2008517921A5 (enExample) | ||
| JP2005532330A5 (enExample) | ||
| ES2321600T3 (es) | El uso cianopirrolidinas sustituidas para tratar hiperlipidemia. | |
| Olsson et al. | Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation | |
| TW200306799A (en) | Combination of organic compounds | |
| JP2023076632A5 (enExample) | ||
| JP2002528502A5 (enExample) | ||
| JP2004514654A5 (enExample) | ||
| TW201202255A (en) | Novel composition for the prevention and/or treatment of thromboembolism | |
| JP2004519424A5 (ja) | インシュリン分泌促進剤およびＨＭＧ−Ｃｏ−Ａレダクターゼ阻害剤およびＡＣＥ阻害剤から選択される活性成分を含む組み合わせ | |
| WO2006104086A1 (ja) | 血栓症治療剤 | |
| KR20060130619A (ko) | 유기 화합물의 조합물 | |
| Pines et al. | ACE inhibition with moexipril: a review of potential effects beyond blood pressure control | |
| RU2006121339A (ru) | Применение ингибиторов дипептидилпептидазы iv | |
| JPH0393719A (ja) | セルトラリンからなる薬物依存症治療剤 | |
| JP2010529125A5 (enExample) | ||
| JP2005503391A5 (enExample) |